Skip to main content
Midas Edge

Werewolf Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Jul 31, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 31, 2026

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity for the and

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(amounts in thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance at December 31, 202548,596,817$5$500,210$(475,410)$24,805
Stock-based compensation expense——929—929
Net loss———(13,532)(13,532)
Balance at March 31, 202648,596,8175501,139(488,942)12,202
Issuance of common stock, net2,249—1—1
Stock-based compensation expense——419—419
Net income———3,6703,670
Balance at June 30, 202648,599,066$5$501,559$(485,272)$16,292
Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance at December 31, 202444,827,159$5$487,973$(414,588)$73,390
Stock-based compensation expense——2,006—2,006
Net loss———(18,089)(18,089)
Balance at March 31, 202544,827,1595489,979(432,677)57,307
Issuance of common stock from at the market offering, net of issuance costs of $255421,766—305—305
Issuance of common stock, net86,340—41—41
Stock-based compensation expense——1,793—1,793
Net loss———(17,982)(17,982)
Balance at June 30, 202545,335,265$5$492,118$(450,659)$41,464
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.